Evidence map›Paper›PMID 32432964›Full record

ArticlemAbs

Investigation of anomalous charge variant profile reveals discrete pH-dependent conformations and conformation-dependent charge states within the CDR3 loop of a therapeutic mAb.

Wenkui Lan, Joseph J Valente, Andrew Ilott, Naresh Chennamsetty, Zhihua Liu, Joseph M Rizzo, Aaron P Yamniuk, Difei Qiu, Holly M Shackman, Mark S Bolgar

Abstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenkui LanDrug Product Development, Bristol Myers Squibb, New Brunswick, United States.
Joseph J ValenteDrug Product Development, Bristol Myers Squibb, New Brunswick, United States.
Andrew IlottDrug Product Development, Bristol Myers Squibb, New Brunswick, United States.
Naresh ChennamsettyBiophysics Center of Excellence, Global Product Development and Supply, Bristol Myers Squibb, New Brunswick, United States.
Zhihua LiuDrug Product Development, Bristol Myers Squibb, New Brunswick, United States.
Joseph M RizzoDiscovery Biotherapeutics, Bristol Myers Squibb, Pennington, United States.
Aaron P YamniukDiscovery Biotherapeutics, Bristol Myers Squibb, Pennington, United States.
Difei QiuChemical Process Department, Bristol Myers Squibb, New Brunswick, United States.
Holly M ShackmanChemical Process Department, Bristol Myers Squibb, New Brunswick, United States.
Mark S BolgarDrug Product Development, Bristol Myers Squibb, New Brunswick, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the development of a therapeutic monoclonal antibody (mAb-1), the charge variant profile obtained by pH-gradient cation exchange chromatography (CEX) contained two main peaks, each of which exhibited a unique intrinsic fluorescence profile and demonstrated inter-convertibility upon reinjection of isolated peak fractions. Domain analysis of mAb-1 by CEX and liquid chromatography-mass spectrometry indicated that the antigen-binding fragment chromatographed as two separate peaks that had identical mass. Surface plasmon resonance binding analysis to antigen demonstrated comparable kinetics/affinity between these fractionated peaks and unfractionated starting material. Subsequent molecular modeling studies revealed that the relatively long and flexible complementarity-determining region 3 (CDR3) loop on the heavy chain could adopt two discrete pH-dependent conformations: an "open" conformation at neutral pH where the HC-CDR3 is largely solvent exposed, and a "closed" conformation at lower pH where the solvent exposure of a neighboring tryptophan in the light chain is reduced and two aspartic acid residues near the ends of the HC-CDR3 loop have atypical pKa values. The pH-dependent equilibrium between "open" and "closed" conformations of the HC-CDR3, and its proposed role in the anomalous charge variant profile of mAb-1, were supported by further CEX and hydrophobic interaction chromatography studies. This work is an example of how pH-dependent conformational changes and conformation-dependent changes to net charge can unexpectedly contribute to perceived instability and require thorough analytical, biophysical, and functional characterization during biopharmaceutical drug product development.

Indexed as

Protein ConformationAnimalsAntibodies, MonoclonalAntigen-Antibody ReactionsCHO CellsChromatography, LiquidComplementarity Determining RegionsCricetinaeCricetulusHumansHydrogen-Ion ConcentrationMass SpectrometryModels, MolecularPeptide MappingRecombinant ProteinsSurface Plasmon ResonanceAntibodies, MonoclonalComplementarity Determining RegionsRecombinant Proteinscation exchange chromatographycharge heterogeneityconformational equilibriumHC-CDR3hydrophobic interaction chromatographypH-dependent conformationsurface plasmon resonancetherapeutic monoclonal antibody

Identifiers

PMID32432964
PMCPMC7299213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.